View Archive »
About The Cover
PKM2 contributes to metabolic reprogramming and cancer progression by serving as a PHD3-dependent coactivator for HIF-1. Prolyl hydroxylation of PKM2 by PHD3 promotes the interaction of PKM2 with HIF-1α, thereby stabilizing HIF-1 binding to the HRE of target genes, recruitment of coactivator p300, histone acetylation, and subsequent transcription of HIF-1 target genes, which encode proteins that are involved in metabolic reprogramming, angiogenesis, and many other critical aspects of cancer progression. See Luo and Semenza.
Table of Contents
Allogeneic adoptive cell transfer therapy as a potent universal treatment for cancer
Allogeneic adoptive cell transfer therapy as a potent universal treatment for cancer |
|
https://doi.org/10.18632/oncotarget.300
Assaf Marcus,
and Zelig Eshhar
|
| 525-526 |
Paracrystals of STAT proteins and their dissolution by SUMO: How reduced transcription factor solubility increases cytokine signaling
Paracrystals of STAT proteins and their dissolution by SUMO: How reduced transcription factor solubility increases cytokine signaling |
|
https://doi.org/10.18632/oncotarget.307
Mathias Droescher,
Andreas Begitt,
and Uwe Vinkemeier
|
| 527-528 |
A breast cancer meta-analysis of two expression measures of chromosomal instability reveals a relationship with younger age at diagnosis and high risk histopathological variables
A breast cancer meta-analysis of two expression measures of chromosomal instability reveals a relationship with younger age at diagnosis and high risk histopathological variables |
|
https://doi.org/10.18632/oncotarget.298
David Endesfelder,
Nicholas McGranahan,
Nicolai Juul Birkbak,
Zoltan Szallasi,
Maik Kschischo,
Trevor Graham,
and Charles Swanton
|
| 529-537 |
Involvement of Akt-1 and mTOR in Sensitivity of Breast Cancer to Targeted Therapy
Involvement of Akt-1 and mTOR in Sensitivity of Breast Cancer to Targeted Therapy |
|
https://doi.org/10.18632/oncotarget.302
Melissa L. Sokolosky,
Kristin M. Stadelman,
William H. Chappell,
Stephen L. Abrams,
Alberto M. Martelli,
Franca Stivala,
Massimo Libra,
Ferdinando Nicoletti,
Lyudmyla B. Drobot,
Richard A. Franklin,
Linda S. Steelman,
and James A. McCubrey
|
| 538-550 |
Pyruvate kinase M2 regulates glucose metabolism by functioning as a coactivator for hypoxia-inducible factor 1 in cancer cells
Pyruvate kinase M2 regulates glucose metabolism by functioning as a coactivator for hypoxia-inducible factor 1 in cancer cells |
|
https://doi.org/10.18632/oncotarget.299
Weibo Luo,
and Gregg L. Semenza
|
| 551-556 |
Targeting cancer with peptide aptamers
Targeting cancer with peptide aptamers |
|
https://doi.org/10.18632/oncotarget.297
Renaud Seigneuric,
Jessica Gobbo,
Pierre Colas,
and Carmen Garrido
|
| 557-561 |
Targeting invadopodia to block breast cancer metastasis
Targeting invadopodia to block breast cancer metastasis |
|
https://doi.org/10.18632/oncotarget.301
Mark A Eckert,
and Jing Yang
|
| 562-568 |
Wnt and Kras signaling-dark siblings in lung cancer
Wnt and Kras signaling-dark siblings in lung cancer |
|
https://doi.org/10.18632/oncotarget.305
Eugenia C. Pacheco-Pinedo,
and Edward E. Morrisey
|
| 569-574 |
Evi1 forms a bridge between the epigenetic machinery and signaling pathways
Evi1 forms a bridge between the epigenetic machinery and signaling pathways |
|
https://doi.org/10.18632/oncotarget.304
Akihide Yoshimi,
and Mineo Kurokawa
|
| 575-586 |
